Synthra MeIPlus Research with HCN/CO Options and Radchrom Plus for the UAB Cyclotron Facility

用于 UAB 回旋加速器设施的 Synthra MeIPlus 研究，具有 HCN/CO 选项和 Radchrom Plus

• 批准号: 10416828
• 负责人: Suzanne Elizabeth Lapi
• 金额: $ 23.67万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-01 至 2023-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10416828
• 关键词: Acetates; Alabama; Amyloid deposition; Brain; Carbon; Carbon Dioxide; Clinical Trials; Cyclotrons; Fostering; Foundations; Funding; Glycoproteins; Goals; Half-Life; Image; Infrastructure; Investments; Label; Magnetic Resonance Imaging; Methane; Methods; Neurodegenerative Disorders; PET/CT scan; Patients; Pharmaceutical Preparations; Phase; Pittsburgh Compound-B; Positron-Emission Tomography; Preparation; Production; Radiolabeled; Radiopharmaceuticals; Reagent; Research; Research Personnel; Synaptic Vesicles; Tracer; Training; United States National Institutes of Health; Universities; amyloid imaging; animal imaging; density; imaging agent; imaging study; methyl iodide; molecular imaging; novel; pre-clinical; research study

Project Summary This proposal seeks support to procure and install a new radiopharmaceutical synthesizer (Synthra Radchrom Plus) capable of producing 11C-radiolabeled drugs for preclinical (small animal imaging) studies and for Phase 0/I/II clinical trials for imaging researchers. Carbon-11 imaging agents are essential for multitude of NIH and other federal and foundation funded research at UAB and due to the short half-life of 11C, the synthesis of these agents must occur onsite. The module will be housed within the UAB cyclotron facility and maintained and operated by highly trained technical staff. The University of Alabama at Birmingham has made significant investments in the infrastructure of molecular imaging including a TR24 cyclotron, PET/CT and PET MRI scanners and a full GMP radiopharmaceutical production facility including a standalone, radiopharmacy. As research studies using 11C compounds have greatly expanded at UAB, the new module will enable the onboarding and robust availability of 11C-imaging agents. In order to maintain and expand upon our current level of high-quality research and to continue to make novel advancements, the acquisition of the Synthra Radchrom Plus is critical for at least 8 NIH funded researchers and a number of additional researchers including a mix of senior and early stage investigators. The new synthesizer will support a wide range of 11C-labeling methods including direct labeling of Grignard reagents (such as for the preparation of 11C-Acetate) and conversion of 11C-CO2 to 11C-Methane, 11C-Methyl iodide and/or 11C-Methyl Triflate, which can be used for a tracers important for NIH funded research such as, 11C-Pittsburgh Compound B ([11C]PiB) used for imaging of amyloid deposition in the brain and 11C-UCB-J, used for imaging synaptic vesicle glycoprotein 2A (SV2A) density in patients with neurodegenerative disease. This proposal is being strongly supported by the University with dedicated space and significant funds ($30,000) from a variety of departments and centers to help support this advancement. Continued support of current ongoing projects, while broadening and extending capabilities to foster new projects is the ultimate goal of the present application.

项目概要 该提案寻求支持采购和安装新的放射性药物合成器（Synthra Radchrom） Plus) 能够生产用于临床前（小动物成像）研究和阶段性的 11C 放射性标记药物 面向影像研究人员的 0/I/II 临床试验。碳 11 显像剂对于许多 NIH 和 其他联邦和基金会资助的 UAB 研究，由于 11C 的半衰期短，这些的合成 代理必须到场。该模块将安装在 UAB 回旋加速器设施内并进行维护和维护 由训练有素的技术人员操作。阿拉巴马大学伯明翰分校取得了重大成就 对分子成像基础设施的投资，包括 TR24 回旋加速器、PET/CT 和 PET MRI 扫描仪和完整的 GMP 放射性药物生产设施，包括独立的放射性药物室。作为 使用 11C 化合物的研究在 UAB 已得到极大扩展，新模块将使 11C 显像剂的加入和强大可用性。为了维持和扩展我们现有的 为了提高高质量研究水平并继续取得新进展，收购了 Synthra Radchrom Plus 对于至少 8 名 NIH 资助的研究人员和许多其他研究人员至关重要，包括 高级和早期研究人员的混合体。新的合成器将支持广泛的 11C 标记 方法包括直接标记格氏试剂（例如用于制备 11C-乙酸盐）和 11C-CO2转化为11C-甲烷、11C-碘甲烷和/或11C-三氟甲磺酸甲酯，可用于 对 NIH 资助的研究很重要的示踪剂，例如用于成像的 11C-匹兹堡化合物 B ([11C]PiB) 大脑中淀粉样蛋白沉积和 11C-UCB-J，用于突触小泡糖蛋白 2A (SV2A) 密度成像 患有神经退行性疾病的患者。这项提议得到了大学的大力支持 来自各个部门和中心的专用空间和大量资金（30,000 美元）来帮助支持这一目标 进步。继续支持当前正在进行的项目，同时扩大和扩展能力 培育新项目是本申请的最终目标。